Details

Autor(en) / Beteiligte

• Aladily, Tariq N
• Medeiros, L Jeffrey
• Amin, Mitual B
• Haideri, Nisreen
• Ye, Dongjiu
• Azevedo, Sergio J
• Jorgensen, Jeffrey L
• de Peralta-Venturina, Mariza
• Mustafa, Eid B
• Young, Ken H
• You, M James
• Fayad, Luis E
• Blenc, Ann Marie
• Miranda, Roberto N

Titel

Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases

Ist Teil von

• The American journal of surgical pathology, 2012-07, Vol.36 (7), p.1000-1008

Ort / Verlag

United States

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• We report 13 cases of anaplastic large cell lymphoma (ALCL) associated with breast implants. Patient age ranged from 39 to 68 years, and the interval from implant to ALCL was 4 to 29 years. All tumors were composed of large, pleomorphic cells that were CD30 and ALK1, and all 7 cases assessed had monoclonal T-cell receptor γ-chain rearrangements. Two patient subgroups were identified. Ten patients presented with effusion surrounded by fibrous capsule without a grossly identifiable tumor mass. Nine patients had stage I and 1 had stage II disease. Eight patients underwent implant removal and capsulectomy. Four patients received chemotherapy and 4 radiation therapy. All patients were alive without disease at last follow-up. A second subgroup of 3 patients had effusion and a distinct mass adjacent to the implant. One patient had stage I and 2 stage II disease. One patient had a 3-year history of lymphomatoid papulosis, and 1 patient had a 1-year history of CD30 T-cell lymphoma adjacent to the breast before the diagnosis of ALCL associated with breast implant. Two patients received chemotherapy and 1 radiation therapy. Two patients died 2 and 12 years after diagnosis, respectively. We conclude that the clinical behavior of ALCL associated with breast implants is heterogeneous. Patients who present with effusion without a distinct mass have an indolent disease course, similar to CD30 lymphoproliferative disorder of skin. In contrast, patients who present with a distinct mass may have advanced stage or possibly systemic disease and have a poorer prognosis.